[Ad hoc announcement pursuant to Art. 53 LR] Roche reports good sales growth in the first quarter of 2022
Group sales increase 11%1 at constant exchange rates (CER) and 10% in Swiss francsPharmaceuticals Divisionsales up 6%; continued strong sales of new medicines for severe diseases. Impact of biosimilars decreases as expected.Diagnostics Divisionsales grow 24% due to good momentum in base business and continued high demand for COVID-19 tests. After a strong first quarter, significant decline in COVID-19-related testing expected.Highlights in the first quarter:FDA approval of Vabysmo (severe eye diseases); CHMP recommends EU approval of Polivy combination (aggressive form of blood cancer), Tecentriq (early-stage non-small cel...
Source: Roche Investor Update - April 25, 2022 Category: Pharmaceuticals Source Type: news
Long-Term Anti-VEGF Delivery System Draws Closer to Primetime Long-Term Anti-VEGF Delivery System Draws Closer to Primetime
The Port Delivery System is a refillable intravitreal implant designed to deliver a continuous supply of ranibizumab into the vitreous. Is it as good as intravitreal ranibizumab injections?Medscape Ophthalmology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 20, 2022 Category: Consumer Health News Tags: Ophthalmology Commentary Source Type: news
New two-year data for Roche ’s Vabysmo and Susvimo reinforce potential to maintain vision with fewer treatments for people with two leading causes of vision loss
Basel, 11 February 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new two-year data from its phase III studies of Vabysmo ™ (faricimab) and Susvimo™ (previously called Port Delivery System with ranibizumab) will be presented at Angiogenesis, Exudation and Degeneration 2022 on 12 February. These longer-term results from the Vabysmo YOSEMITE and RHINE studies in diabetic macular edema (DME) and the Susvimo Archway st udy in neovascular or “wet” age-related macular degeneration (nAMD) further reinforce the potential to allow for longer time between treatments and fewer eye injections for people with th...
Source: Roche Investor Update - February 11, 2022 Category: Pharmaceuticals Source Type: news
New two-year data for Roche ’s Vabysmo and Susvimo reinforce potential to maintain vision with fewer treatments for people with two leading causes of vision loss
This study will evaluate the efficacy, safety, and pharmacokinetics of the port delivery system with ranibizumab in participants with diabetic macular edema compared with intravitreal ranibizumab (Pagoda) [Internet; cited January 2022]. Available from:https://clinicaltrials.gov/ct2/show/NCT04108156.[14] ClinicalTrials.gov. A multicenter, randomized study in participants with diabetic retinopathy without center-involved diabetic macular edema to evaluate the efficacy, safety, and pharmacokinetics of ranibizumab delivered via the port delivery system relative to the comparator arm (PAVILION) [Internet; cited January 2022]. A...
Source: Roche Investor Update - February 11, 2022 Category: Pharmaceuticals Source Type: news
New two-year data for Roche ’s Vabysmo and Susvimo reinforce potential to maintain vision with fewer treatments for people with two leading causes of vision loss
This study will evaluate the efficacy, safety, and pharmacokinetics of the port delivery system with ranibizumab in participants with diabetic macular edema compared with intravitreal ranibizumab (Pagoda) [Internet; cited January 2022]. Available from:https://clinicaltrials.gov/ct2/show/NCT04108156.[14] ClinicalTrials.gov. A multicenter, randomized study in participants with diabetic retinopathy without center-involved diabetic macular edema to evaluate the efficacy, safety, and pharmacokinetics of ranibizumab delivered via the port delivery system relative to the comparator arm (PAVILION) [Internet; cited January 2022]. A...
Source: Roche Media News - February 11, 2022 Category: Pharmaceuticals Source Type: news
New two-year data for Roche ’s Vabysmo and Susvimo reinforce potential to maintain vision with fewer treatments for people with two leading causes of vision loss
Basel, 11 February 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new two-year data from its phase III studies of Vabysmo ™ (faricimab) and Susvimo™ (previously called Port Delivery System with ranibizumab) will be presented at Angiogenesis, Exudation and Degeneration 2022 on 12 February. These longer-term results from the Vabysmo YOSEMITE and RHINE studies in diabetic macular edema (DME) and the Susvimo Archway st udy in neovascular or “wet” age-related macular degeneration (nAMD) further reinforce the potential to allow for longer time between treatments and fewer eye injections for people with th...
Source: Roche Media News - February 11, 2022 Category: Pharmaceuticals Source Type: news
[Ad hoc announcement pursuant to Art. 53 LR] Roche reports good results in 2021
Basel, 3 February 2022Group sales increase 9%1 at constant exchange rates (CER); 8% in Swiss francsPharmaceuticals Divisionsales increase 3%; continued strong demand for newly launched medicines more than offsets impact of biosimilarsDiagnostics Divisionsales grow 29%; strong momentum in base business and continued high demand for COVID-19 testsMajor approvals for medicinessince the last quarter:United States: Susvimo and Vabysmo (age-related blindness)Europe: Gavreto (specific type of advanced lung cancer); Actemra/RoActemra (severe COVID-19); Ronapreve (non-hospitalised COVID-19 patients and prophylaxis)Major approvals f...
Source: Roche Media News - February 3, 2022 Category: Pharmaceuticals Source Type: news
FDA approves Roche ’s Vabysmo, the first bispecific antibody for the eye, to treat two leading causes of vision loss
Vabysmo (faricimab-svoa) targetsand inhibitstwodiseasepathways that drive neovascular or “wet” age-related macular degeneration (nAMD) and diabetic macular edema (DME)Vabysmo is the only injectable eye medicine approved simultaneously in the US for nAMD and DME, with flexible dosing regimens based on patient needBasel, 31 January 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has approved Vabysmo™ (faricimab-svoa) for the treatment of neovascular or “wet” age-related macular degeneration (nAMD) and diabetic macular edema (DME). Neovascular AMD and DM E...
Source: Roche Media News - January 31, 2022 Category: Pharmaceuticals Source Type: news
FDA approves Roche ’s Vabysmo, the first bispecific antibody for the eye, to treat two leading causes of vision loss
Vabysmo (faricimab-svoa) targetsand inhibitstwodiseasepathways that drive neovascular or “wet” age-related macular degeneration (nAMD) and diabetic macular edema (DME)Vabysmo is the only injectable eye medicine approved simultaneously in the US for nAMD and DME, with flexible dosing regimens based on patient needBasel, 31 January 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has approved Vabysmo™ (faricimab-svoa) for the treatment of neovascular or “wet” age-related macular degeneration (nAMD) and diabetic macular edema (DME). Neovascular AMD and DM E...
Source: Roche Investor Update - January 31, 2022 Category: Pharmaceuticals Source Type: news
The Lancet publishes studies showing Roche ’s faricimab improved and maintained vision in two leading causes of vision loss, extending time between treatments up to four months
Two papers in The Lancet highlight one-year results from Roche ’s phase III trials evaluatingfaricimab inneovascular or “wet” age-related macular (nAMD) and diabetic macular edema (DME)Across four studies, about half of eligiblefaricimab patients were able to go four months between treatments, and approximately three-quarters could be treated every three months or longerReductions in central subfield thickness (CST) and resolution ofintraretinal fluid consistentlyfavouredfaricimab overaflibercept in DME, and meaningful and comparable CST reductions were seen innAMD in the first yearBasel, 24 January 2022 - Roche (SIX...
Source: Roche Investor Update - January 24, 2022 Category: Pharmaceuticals Source Type: news
The Lancet publishes studies showing Roche ’s faricimab improved and maintained vision in two leading causes of vision loss, extending time between treatments up to four months
Two papers in The Lancet highlight one-year results from Roche ’s phase III trials evaluatingfaricimab inneovascular or “wet” age-related macular (nAMD) and diabetic macular edema (DME)Across four studies, about half of eligiblefaricimab patients were able to go four months between treatments, and approximately three-quarters could be treated every three months or longerReductions in central subfield thickness (CST) and resolution ofintraretinal fluid consistentlyfavouredfaricimab overaflibercept in DME, and meaningful and comparable CST reductions were seen innAMD in the first yearBasel, 24 January 2022 - Roche (SIX...
Source: Roche Media News - January 24, 2022 Category: Pharmaceuticals Source Type: news
Class 2 Medicines Recall: Novartis Pharmaceuticals UK, Lucentis 10 mg/ml solution for injection in pre-filled syringe
Novartis Pharmaceuticals UK are recalling a specified batch of Lucentis 10 mg/ml solution for injection in pre-filled syringe due to a faulty plunger stopper which has led to an increased number of cu (Source: Royal Pharmaceutical Society News)
Source: Royal Pharmaceutical Society News - December 13, 2021 Category: Drugs & Pharmacology Source Type: news
Bevacizumab-vikg Wet AMD Trial Raises Eyebrows Bevacizumab-vikg Wet AMD Trial Raises Eyebrows
An ' apples-to-oranges ' comparison of bevacizumab-vikg to ranibizumab is troubling some experts who would like to see the drug approved.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 14, 2021 Category: Consumer Health News Tags: Ophthalmology News Source Type: news
Susvimo (ranibizumab)
Title: Susvimo (ranibizumab)Category: MedicationsCreated: 10/27/2021 12:00:00 AMLast Editorial Review: 10/27/2021 12:00:00 AM (Source: MedicineNet Eyesight General)
Source: MedicineNet Eyesight General - October 27, 2021 Category: Opthalmology Source Type: news
